ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.
about
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraThe molecular biology of thrombotic microangiopathyPathogenesis of thrombotic microangiopathiesProteolytic processing of von Willebrand factor by adamts13 and leukocyte proteasesRelationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.ADAMTS13 and microvascular thrombosisADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpuraRemission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiencyThe potential utility of B cell-directed biologic therapy in autoimmune diseases.Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.Antiphospholipid antibodies: paradigm in transition.Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience[Thrombotic-thrombocytopenic purpura].Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.[ADAMTS13, von Willebrand factor specific cleaving protease].The role of human leukocyte antigens as predisposing and/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura.Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome.Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjögren's syndrome: two cases and a literature review.Atypical thrombotic thrombocytopenic purpura in a middle-aged woman who presented with a recurrent stroke.ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.Presence of anti-ADAMTS13 antibodies in obesity.Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.A novel Wiskott-Aldrich syndrome protein mutation in an infant with thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura-what is new?Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim.Management of pregnancy-associated thrombotic thrombocytopenia purpura.Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research.Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.Defective ADAMTS13 synthesis as a possible consequence of NASH in an obese patient with recurrent thrombotic thrombocytopenic purpura.A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay.Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.Understanding organ dysfunction in thrombotic thrombocytopenic purpura.Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
P2860
Q24620546-2A6D093E-A4AD-4454-9FA9-65FB4BA5EDCFQ24648686-339EE7FE-E574-4472-8BE5-3A4134C877D1Q24658043-9E72C6C8-FA8D-4256-9238-1ADBE55DD6CBQ26827966-3E64E494-DD92-4387-AEBC-F9969EBB8533Q33327295-16614699-57F8-4A33-AE4A-50D6E01B67F0Q33369765-B10EE227-2C38-4EB1-8556-D7A5933EF9FEQ33371103-C6641723-032E-4683-9C90-3BC7E248EBD1Q33372115-3F9BD7E6-C6CE-4A97-A1F6-12F68D456517Q33373608-A83FA5CB-2DCD-4C95-BA86-8DC5D8E1D479Q33373698-115C7F3F-6243-4551-B80D-AEA69E4819E0Q33373912-D271919F-9039-4F53-8D72-8386B4245343Q33376071-22DA2C39-04BE-4B99-9865-F839D1F78E23Q33377109-93D0B5B3-84D0-4214-BAC2-302C7DA77F41Q33380771-7F61C660-81B4-4B1F-B963-85925365E5A4Q33382848-80712FC4-489D-404F-9FA6-804FB68917D9Q33389392-DCB734B0-C5E5-4D18-8AD5-ACD1B58096C0Q33391233-7BD27EC2-E60B-4547-92AD-C6561248C754Q33393992-B301F17A-20DB-4B20-93DA-61844303B537Q33395145-28ECD420-D351-4ED3-AE9E-B4DEAE34F8C9Q33397081-1CA2C4C5-4E6E-4C82-BD0E-FF3465119FADQ33398887-8BD267A1-0ADE-47B1-80EB-A30FABA9A091Q33398942-F079D758-4844-4603-A5C9-93559DBCFFA4Q33398993-D52331E4-8DDC-4291-A9BF-632D91C784AEQ33400882-03188D34-BC29-49FB-85DB-CF763B4A7FD2Q33401469-CD667BD9-1CDD-4CC5-A1EA-800BEBDE02D0Q33401647-E8731DC7-FE4C-44F2-8B4F-7F71422CC413Q33403187-775990CC-8DBF-4C45-AE35-ADFD55E6833EQ33404118-4D88633E-EF23-4055-8E3D-B4380C74BEFAQ33404827-243D0895-F2B4-4CE9-A86B-C2DFE8B0C040Q33405965-08A79FA6-87A9-4E9D-A04F-EB9E74BB2D5FQ33406819-488E70CF-24E4-457F-8829-352C9D6D8BD4Q33409773-27D60ED1-8710-4408-94A2-F48985E5F8C1Q33411009-F90F1842-C1F4-46E5-AF16-A215969B8FF5Q33411525-D02C9EF6-C28C-4252-86D3-F54E2D2FE344Q33412212-8D6A0678-52B3-4B20-B495-6FEB67924DCCQ33412873-11CF21D1-8B02-41CC-BC4B-F18155B41814Q33416555-4578DD89-951C-4AE3-A77C-2CA1E4FE0E94Q33416588-7FC8CE8B-193C-4F8F-B492-5B5AD5CA885AQ33419860-5825B789-4EE2-4572-8405-9CAA698DC46BQ33421577-C9547C36-5C36-411E-8052-1D3C9B38515C
P2860
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
ADAMTS13 autoantibodies in pat ...... other immunomediated diseases.
@ast
ADAMTS13 autoantibodies in pat ...... other immunomediated diseases.
@en
type
label
ADAMTS13 autoantibodies in pat ...... other immunomediated diseases.
@ast
ADAMTS13 autoantibodies in pat ...... other immunomediated diseases.
@en
prefLabel
ADAMTS13 autoantibodies in pat ...... other immunomediated diseases.
@ast
ADAMTS13 autoantibodies in pat ...... other immunomediated diseases.
@en
P2093
P50
P1433
P1476
ADAMTS13 autoantibodies in pat ...... other immunomediated diseases.
@en
P2093
Andrea Herzog
Christian Konetschny
Friedrich Scheiflinger
Gabi Gerstenbauer
Inge Scharrer
Klaus Zimmermann
Manfred Rieger
Martina Böhm
Miriam Galbusera
P304
P356
10.1182/BLOOD-2004-11-4490
P407
P50
P577
2005-05-12T00:00:00Z